Previous 10 | Next 10 |
CytoDyn ([[CYDY]]) announces that it has executed an exclusive supply and distribution agreement with Chiral Pharma to supply up to 200K vials of leronlimab to critically ill COVID-19 patients in the Philippines under Compassionate Special Permit ((CSP))authorizations."......
CytoDyn ([[CYDY]] -11.6%) has announced the full enrollment of a Phase 2 trial evaluating Vyrologix (Leronlimab) in the treatment of patients with prolonged COVID-19 symptoms.The randomized, double-blind, placebo-controlled study involving 56 patients is designed to evaluate the safety a...
VANCOUVER, Washington, April 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced tod...
CytoDyn ([[CYDY]] -11.2%) is to deliver its experimental COVID-19 therapy Leronlimab (PRO 140) to a Philippine hospital for the treatment of an additional 28 critically ill COVID-19 patients under a new Compassionate Special Permit, the company said.Chiral Pharma, the importer of Leronli...
CytoDyn also negotiating the potential future delivery of 100,000 vials to the Philippines for additional CSP use VANCOUVER, Washington, April 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology...
CytoDyn (CYDY) has executed an exclusive supply and distribution agreement with Biomm S.A. in Brazil, enabling Biomm to sell leronlimab in the region following regulatory clearance. CYDY has committed to conduct clinical trials in Brazil for all current indications for leronlimab (i...
VANCOUVER, Washington, April 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced tod...
If You Like Biotech Penny Stocks, Check These 3 Out Biotech penny stocks are some of the most popular securities in the stock market right now. Within the industry, many different companies are working on a large range of projects. Traders should understand that investing in biotech can...
VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic ...
Late March, CytoDyn ([[CYDY]] +24.5%) announced that the Philippines FDA approved the use of Vyrologix (leronlimab) to treat a COVID-19 patient under compassionate special permit.38 hours after the subcutaneous injection of leronlimab, the patient has ‘significantly’ i...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...